Kuros BiosciencesCSBTF 71 Return-on-Tangible-Equity is 23.47% as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $48.29 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 59.68% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kuros Biosciences's annualized net income for the quarter that ended in Dec. 2025 was $10.4 Mil. Kuros Biosciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $44.5 Mil. Therefore, Kuros Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 23.47%.
The historical rank and industry rank for Kuros Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
CSBTF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -246.53 Med: -63.82 Max: 7.8
Current: 7.8
During the past 13 years, Kuros Biosciences's highest Return-on-Tangible-Equity was 7.80%. The lowest was -246.53%. And the median was -63.82%.
CSBTF's Return-on-Tangible-Equity is ranked better than 59.68% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs CSBTF: 7.80
Kuros Biosciences (OTCPK:CSBTF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Kuros Biosciences Return-on-Tangible-Equity Related Terms
Kuros Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Kuros Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 23.47% mean?
Kuros Biosciences (CSBTF) has a Return-on-Tangible-Equity of 23.47% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #306 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 40.3%.
Is Kuros Biosciences' Return-on-Tangible-Equity too high?
Kuros Biosciences' current Return-on-Tangible-Equity is 23.47%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Kuros Biosciences' value of 23.47% is 473.8% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #306 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #306 out of 759 companies for Return-on-Tangible-Equity. This puts Kuros Biosciences in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.09. Kuros Biosciences' value of 23.47% is 473.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Return-on-Tangible-Equity of 23.47% is 473.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Return-on-Tangible-Equity is 23.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.29, compared to a current price of $22.72 — trading 53% below its estimated fair value. The current Return-on-Tangible-Equity is 23.47% and 473.8% above the Medical Devices & Instruments industry median of 4.09. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Return-on-Tangible-Equity is 23.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 53% below its estimated GF Value™ of $48.29.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Return-on-Tangible-Equity: 23.47%
GF Value™: $48.29 vs. price of $22.72 (53% below fair value)
Industry Position: 473.8% above the Medical Devices & Instruments median (#306 of 759)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
